Clinical Trial Update: Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating nivolumab with or without pazopanib in metastatic or unresectable soft tissue sarcoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• OPDIVO (nivolumab)
• Votrient (Pazopanib)

Snippet

Sponsor: NYU Langone Health | Conditions: Soft Tissue Sarcomas | Phase 2 | Status: WITHDRAWN